THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Darryl D'Lima: Scripps Health Every year millions of Americans suffer damage to their cartilage, either in their knee or other joints, that can eventually lead to osteoarthritis, pain and immobility. Today the governing Board of the California Institute for Regenerative Medicine (CIRM) approved two projects targeting … Continue reading Two Early-Stage Research Programs Targeting Cartilage Damage Get Funding from Stem Cell Agency
T-cells
Making stem cell and gene therapies available and affordable for all California patients
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Developing a new therapy: Photo courtesy UCLA There is no benefit in helping create a miraculous new therapy that can cure people and save lives if no one except the super-rich can afford it. That’s why the California Institute for Regenerative Medicine (CIRM) has made creating … Continue reading Making stem cell and gene therapies available and affordable for all California patients
Stem Cell Agency Board Invests in Therapy Targeting Deadly Blood Cancers
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Dr. Ezra Cohen, photo courtesy UCSD Hematologic malignancies are cancers that affect the blood, bone marrow and lymph nodes and include different forms of leukemia and lymphoma. Current treatments can be effective, but in those patients that do not respond, there are few treatment options. Today, … Continue reading Stem Cell Agency Board Invests in Therapy Targeting Deadly Blood Cancers
CIRM funds clinical trials targeting heart disease, stroke and childhood brain tumors
Gary Steinberg (Jonathan Sprague) Heart disease and stroke are two of the leading causes of death and disability and for people who have experienced either their treatment options are very limited. Current therapies focus on dealing with the immediate impact of the attack, but there is nothing to deal with the longer-term impact. The CIRM … Continue reading CIRM funds clinical trials targeting heart disease, stroke and childhood brain tumors
Improving a special kind of cell to help combat immune related problems
Regulatory T cells (Tregs) are a type of immune cell that play an extremely important role in maintaining stability in the body and preventing the body's immune system from attacking its own cells and organs. This unique property makes Tregs extremely valuable to researchers as a potential treatment for immune related issues. One of these … Continue reading Improving a special kind of cell to help combat immune related problems
Latest CIRM TRAN1 awards focus on CAR-based cell therapy to treat cancer
Earlier this week the CIRM ICOC Board awarded $14.5 million to fund three translational stage research projects (TRAN1), whose goal is to support early development activities necessary for advancement to a clinical study or broad end use of a potential therapy. Although all three projects have their distinct area of focus, they all utilize CAR-based … Continue reading Latest CIRM TRAN1 awards focus on CAR-based cell therapy to treat cancer
CIRM Board Approves Clinical Trials for Blood Cancer and Pediatric Brain Tumors
Today the governing Board of the California Institute for Regenerative Medicine (CIRM) awarded $14.4 million for two new clinical trials for blood cancer and pediatric brain tumors. These awards bring the total number of CIRM-funded clinical trials to 70. $6.0 million was awarded to Immune-Onc Therapeutics to conduct a clinical trial for patients with acute … Continue reading CIRM Board Approves Clinical Trials for Blood Cancer and Pediatric Brain Tumors
CIRM funding helps improve immune cell therapy to combat HIV
Image description: T cell infected with HIV. Image Credit: National Institute of Allergy and Infectious Diseases (NIAID) In June of last year we wrote about how Dr. Scott Kitchen and his team at UCLA are engineering blood forming stem cells in order to fight HIV, a potentially deadly virus that attacks the immune system and … Continue reading CIRM funding helps improve immune cell therapy to combat HIV
CIRM-funded treatment gets orphan drug and rare pediatric disease designations from FDA
From left to right: Brian Lookofsky, Taylor Lookofsky, and Rosa Bacchetta, M.D. Picture taken in October 2019 Last year, CIRM awarded $5.53 million to Rosa Bacchetta, M.D. at Stanford University to complete the work necessary to conduct a clinical trial for IPEX syndrome, a rare pediatric disease. This rare disease is caused by mutations in the FOXP3 gene, … Continue reading CIRM-funded treatment gets orphan drug and rare pediatric disease designations from FDA
Partners in health
From left to right: Heather Dahlenburg, staff research associate; Jan Nolta, director of the Stem Cell Program; Jeannine Logan White, advanced cell therapy project manager; Sheng Yang, graduate student, Bridges Program, Humboldt State University, October 18, 2019. (AJ Cheline/UC Davis) At CIRM we are modest enough to know that we can't do everything by ourselves. … Continue reading Partners in health